StockData

Endonovo Therapeutics, Inc. (ENDV) stock

ENDVOTCElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Financials through Q3 FY2023, quarter ended Sep 30, 2023Last filing: 10-Q/A on Dec 29, 2023
$0.00+0.00 (0.00%)

Close on Oct 19, 2026Market cap $135.08KP/E –Yield –

Endonovo Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Endonovo Therapeutics's revenue for the twelve months ending Sep 30, 2023 was $255.72K, up 1699.9% year over year. For fiscal 2022 it was $135.36K, up 85.2% from the year before. Over ten years it grew 10.2% a year on average. The highest annual figure on record is $310.16K in fiscal 2019.

Annual revenue

PeriodPeriod endValueChange
FY2022Dec 31, 2022$135.36K+85.2%
FY2021Dec 31, 2021$73.11K-55.9%
FY2020Dec 31, 2020$165.80K-46.5%
FY2019Dec 31, 2019$310.16K+272.5%
FY2018Dec 31, 2018$83.26K+1852.2%
FY2015Dec 31, 2015$4.27K-82.4%
FY2014Dec 31, 2014$24.19K+5.7%
FY2013Dec 31, 2013$22.90K-25.1%
FY2012Dec 31, 2012$30.58K-32.9%
FY2011Dec 31, 2011$45.54K-11.0%
FY2010Dec 31, 2010$51.20K–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2023Sep 30, 2023$1.52K-86.1%
Q2 FY2023Jun 30, 2023$45.20K+6853.8%
Q1 FY2023Mar 31, 2023$87.54K+3736.1%
Q4 FY2022Dec 31, 2022$121.46K+38337.7%
Q3 FY2022Sep 30, 2022$10.96K+40.7%
Q2 FY2022Jun 30, 2022$650-97.9%
Q1 FY2022Mar 31, 2022$2.28K-93.4%
Q4 FY2021Dec 31, 2021$316-97.3%
Q3 FY2021Sep 30, 2021$7.79K-80.5%
Q2 FY2021Jun 30, 2021$30.28K-32.1%
Q1 FY2021Mar 31, 2021$34.72K-50.2%
Q4 FY2020Dec 31, 2020$11.50K-92.3%
Q3 FY2020Sep 30, 2020$39.98K-26.0%
Q2 FY2020Jun 30, 2020$44.63K-28.9%
Q1 FY2020Mar 31, 2020$69.69K+55.0%
Q4 FY2019Dec 31, 2019$148.44K+252.3%
Q3 FY2019Sep 30, 2019$54.04K+153.6%
Q2 FY2019Jun 30, 2019$62.73K+388.0%
Q1 FY2019Mar 31, 2019$44.95K+544.8%
Q4 FY2018Dec 31, 2018$42.13K+1434.8%
Q3 FY2018Sep 30, 2018$21.31K+3.2%
Q2 FY2018Jun 30, 2018$12.85K-21.7%
Q1 FY2018Mar 31, 2018$6.97K-60.7%
Q1 FY2015Mar 31, 2015$2.75K-88.0%
Q3 FY2014Sep 30, 2014$20.64K–
Q2 FY2014Jun 30, 2014$16.42K–
Q1 FY2014Mar 31, 2014$17.76K–
Q4 FY2013Dec 31, 2013$22.90K–
Q3 FY2013Sep 30, 2013$0–
Q2 FY2013Jun 30, 2013$0–
Q1 FY2013Mar 31, 2013$0–

More Endonovo Therapeutics figures

See a number that looks wrong?